Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

PLoS Pathogens(2022)10.1371/journal.ppat.1010547Source: DataRank Database

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19 is a research paper published in PLoS Pathogens (2022). On theSindex it has a DataRank of 0. It has been cited 33 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access33 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 3.19)OA: goldTopics (21)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Frank Tacke ORCID,Alexandra O’Sullivan,Patrick Dorr,William Ferguson ORCID,William G. Powderly ORCID

Live enrichment

PubMed:35749425 PMC:PMC9231801 OpenAlex:https://openalex.org/W4283366675

AbbVie

FWCI

3.19

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010547&type=printable

GOLDhttps://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010547&type=printable

publisherhttps://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1010547&type=printable

publisherhttps://dx.plos.org/10.1371/journal.ppat.1010547

journalhttps://doi.org/10.1371/journal.ppat.1010547

Fields of Study

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19Medicine

MeSH Terms

SARS-CoV-2COVID-19 Drug TreatmentHumansImidazolesSulfoxidesReceptors, CCR5Receptors, CCR2CCR5 Receptor Antagonists

Keywords

MedicineCCR2Clinical trialCCR5 receptor antagonistChemokine receptorImmunologyChemokineInternal medicineInflammation

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Inhibition of CCR2 attenuates neuroinflammation and neuronal apoptosis after subarachnoid hemorrhage through the PI3K/Akt pathway

10.6084/m9.figshare.22612478.v1figshare

Additional file 1 of Inhibition of CCR2 attenuates neuroinflammation and neuronal apoptosis after subarachnoid hemorrhage through the PI3K/Akt pathway

10.6084/m9.figshare.22612478figshare

Additional file 2 of Inhibition of CCR2 attenuates neuroinflammation and neuronal apoptosis after subarachnoid hemorrhage through the PI3K/Akt pathway

10.6084/m9.figshare.22612481figshare

Additional file 2 of Inhibition of CCR2 attenuates neuroinflammation and neuronal apoptosis after subarachnoid hemorrhage through the PI3K/Akt pathway

10.6084/m9.figshare.22612481.v1figshare

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19

FAIR Checklist

Authors (6)

Funding (1 grants)

Impact

Open Access

Topics

Linked Datasets (4)

Annotations (Europe PMC)